[倍他洛尔制剂降压效果的临床评估]
[Clinical evaluation of the hypotensive effectiveness of Betoptic preparation].
作者信息
Erichev V P, Abdulkadyrova M D, Kalinina O M, Shmyreva V F, Polutornov A L, Egorov E A, Shmeleva I A
出版信息
Vestn Oftalmol. 1991 Nov-Dec;107(6):8-11.
PMID:1781135
Abstract
Clinical trials of the hypotensive effect of 0.5% betoptic, an antiglaucoma drug manufactured by Alcon (USA), were carried out at three ophthalmologic hospitals. Similar results obtained in all the trials permit a conclusion on a high hypotensive efficacy of this drug in patients with primary open-angle glaucoma. The drug was well tolerated by the patients.
摘要
由美国爱尔康公司生产的抗青光眼药物0.5%倍他洛尔的降压效果临床试验在三家眼科医院进行。所有试验获得的相似结果使得可以得出结论，该药物对原发性开角型青光眼患者具有很高的降压疗效。患者对该药物耐受性良好。
Zotero 插件